Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of four statin drugs—simvastatin, atorvastatin, rosuvastatin, and pravastatin. Each is an HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol and reduce cardiovascular risk. Statins work by inhibiting the enzyme HMG-CoA reductase in the liver, which plays a central role in cholesterol biosynthesis. This leads to decreased cholesterol production and increased clearance of LDL from the bloodstream. While each statin has unique pharmacokinetic properties and potential for drug interactions, their primary mechanism is shared. There are no known approved pharmaceutical products that combine all four agents into a single formulation; such use would be highly unusual due to overlapping mechanisms and increased risk of adverse effects such as myopathy or rhabdomyolysis[2][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on simvastatin + atorvastatin + rosuvastatin + pravastatin.